Patient groups urge Congress to reauthorize Prescription Drug User Fee Act, improve clinical trial diversity

Moffitt receives $22.4M grant to advance research and clinical trials for leptomeningeal disease

Researchers at Moffitt Cancer Center have been awarded a $22.4 million grant from the U.S. Department of War to lead studies and clinical trials for leptomeningeal disease, a devastating complication of breast and other cancers that spreads to the coverings of the brain and spinal cord.

October 10, 2025

Vol.51 No.37

Clinical Roundup

Datroway improves OS as first-line therapy in metastatic TNBC, phase III trial shows

Positive high-level results from the Tropion-Breast02 phase III trial showed Datroway (datopotamab deruxtecan-dlnk) demonstrated a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival compared to investigator’s choice of chemotherapy as first-line treatment for patients with locally recurrent inoperable or metastatic triple-negative breast cancer for whom immunotherapy was not an option.

October 10, 2025

Vol.51 No.37

Clinical Roundup

Five-treatment radiation regimen poised to become standard of care, phase III data show

Men with intermediate-risk prostate cancer can receive a complete course of radiation in just five treatments—rather than the typical 20 to 28—while maintaining excellent cancer control and improving quality of life, according to results of an international phase III trial conducted by Rodney J. Ellis.

October 10, 2025

Vol.51 No.37

Clinical Roundup

Alliance trial aims to improve outcomes in metastatic prostate cancer

The Alliance for Clinical Trials in Oncology has launched the ASPIRE trial—a large-scale, phase III clinical study investigating whether adding chemotherapy to current standard treatments can extend survival for men living with advanced prostate cancer.

October 10, 2025

Vol.51 No.37

Clinical Roundup

Tecvayli + Darzalex Faspro achieves 100% MRD negativity in newly diagnosed MM, phase II study shows

An investigational immune-based induction regimen with Tecvayli (teclistamab-cqyv) and Darzalex Faspro (daratumumab and hyaluronidase-fihj) demonstrated meaningful clinical efficacy in transplant-eligible patients with newly diagnosed multiple myeloma.

September 26, 2025

Vol.51 No.35

Podcast

Congress seems to have NCI’s back—is cautious optimism warranted? Two former directors say yes.

With the fiscal year drawing to a close, grant funding from NCI is picking up speed, offering a glimmer of hope to cancer researchers who are beginning to feel cautiously optimistic about the road ahead.

September 24, 2025

Vol.51 No.34

Patient groups urge Congress to reauthorize Prescription Drug User Fee Act, improve clinical trial diversity

YOU MAY BE INTERESTED IN

Moffitt receives $22.4M grant to advance research and clinical trials for leptomeningeal disease

Datroway improves OS as first-line therapy in metastatic TNBC, phase III trial shows

Five-treatment radiation regimen poised to become standard of care, phase III data show

Alliance trial aims to improve outcomes in metastatic prostate cancer

Tecvayli + Darzalex Faspro achieves 100% MRD negativity in newly diagnosed MM, phase II study shows

Congress seems to have NCI’s back—is cautious optimism warranted? Two former directors say yes.

Renew today!

Subscriber content

Never miss an issue!

Login